Guay D R
Section of Clinical Pharmacology, St. Paul-Ramsey Medical Center, MN 55101, USA.
Ann Pharmacother. 1996 Jul-Aug;30(7-8):819-30. doi: 10.1177/106002809603000721.
To review the epidemiology, clinical manifestations, diagnosis, and treatment of nontuberculous mycobacterial infections other than Mycobacterium avium complex (MAC).
A MEDLINE search of English-language literature pertaining to nontuberculous mycobacteria other than MAC was performed. Additional literature was obtained from reference lists of pertinent articles identified through the search.
All articles were considered for possible inclusion in the review. Information judged by the author to be pertinent was selected for discussion.
Mycobacterial infections, including those caused by nontuberculous mycobacteria other than MAC, have assumed greater importance over the past decade, due in part to the changing spectrum of immunosuppression as manifested by organ transplantation and HIV infection. Many pathogenic nontuberculous mycobacteria have been identified that are associated with a wide variety of localized, organ-specific, and systemic infections. Of concern, these organisms exhibit variable, species-specific susceptibility to traditional antimycobacterial drugs and other antimicrobials. In addition, long treatment courses and adjunctive surgical therapy are often required to effect cure. Important antimicrobials for the management of these infections include cefoxitin, imipenem/cilastatin, aminoglycosides (other than streptomycin), tetracyclines, macrolides, and trimethoprim/sulfamethoxazole, as well as traditional antimycobacterials.
Nontuberculous mycobacteria have assumed an increasing role in disease etiology in both nonimmunocompromised and immunocompromised individuals. Advent of rapid diagnostic techniques and susceptibility testing has allowed the clinician to identify these organisms and initiate effective treatment on a more timely basis with an improved chance for cure. Few therapeutic agents are available for treatment of these infections, many of which are not considered classic antimycobacterials.
综述鸟分枝杆菌复合体(MAC)以外的非结核分枝杆菌感染的流行病学、临床表现、诊断及治疗。
对与MAC以外的非结核分枝杆菌相关的英文文献进行了MEDLINE检索。通过检索确定的相关文章的参考文献列表中获取了其他文献。
所有文章均被考虑纳入综述。作者认为相关的信息被选作讨论内容。
分枝杆菌感染,包括由MAC以外的非结核分枝杆菌引起的感染,在过去十年中变得越发重要,部分原因是器官移植和HIV感染所表现出的免疫抑制谱的变化。已鉴定出许多致病性非结核分枝杆菌,它们与多种局部、器官特异性和全身性感染相关。值得关注的是,这些微生物对传统抗分枝杆菌药物和其他抗菌药物表现出不同的、种属特异性的敏感性。此外,通常需要较长的治疗疗程和辅助手术治疗才能实现治愈。用于治疗这些感染的重要抗菌药物包括头孢西丁、亚胺培南/西司他丁、氨基糖苷类(除链霉素外)、四环素类、大环内酯类、甲氧苄啶/磺胺甲恶唑以及传统抗分枝杆菌药物。
非结核分枝杆菌在非免疫受损和免疫受损个体的疾病病因中发挥着越来越重要的作用。快速诊断技术和药敏试验的出现使临床医生能够识别这些微生物,并更及时地开始有效的治疗,治愈机会增加。可用于治疗这些感染的治疗药物很少,其中许多不被认为是经典的抗分枝杆菌药物。